A chart posted exactly a year ago (Post#35563247) related movements in the RAP share price to a simple Fibonacci extension analysis based on the definitive 19.0c peak of April 2018.
Updated a year on, the pattern displays breakaway gaps, in both directions, in which the various Fib levels have remained valid and have defined set price ranges of support and resistance.
Recent CE approval saw the price gap to above the key 19.0c level, which looks to be the support base for the current price range.
Opinions will vary on what effect upcoming announcements of OSA trial results or of FDA approval might have. Mine is that good OSA results would see the price jump again into a higher range with the 100% level at 31.0c probably acting as a cap.
FDA approval however I think would be sufficiently significant to see the price break out above that level, with subsequent adult regulatory approvals, commercial contracts and expanding revenues then acting to continually push the price upwards from there.
- Forums
- ASX - By Stock
- RAP
- rap chart
rap chart, page-1266
-
- There are more pages in this discussion • 3,376 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online